Shanghai Annova Biotechnology patents new ATR kinase inhibitors for cancer
July 24, 2023
Shanghai Annova Biotechnology Co. Ltd. has disclosed substituted fused heterocyclic compounds acting as ATR kinase inhibitors reported to be useful for the treatment of cancer.